dlt446 dlt446

dlt446 dlt446

Clinical Professor

Member of:

  • Neurology


Publication year:
All
11 - 13 out of 13Page size: 10
  1. 2024
  2. Published

    Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial

    dlt446, dlt446, Lipton, R. B., Ailani, J., Versijpt, J., Sacco, S., Mitsikostas, D. D., Christoffersen, C. L., Sperling, B. & Ettrup, A., 2024, In: European Journal of Neurology. 31, 2, e16131.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials

    Rizzoli, P., Marmura, M. J., Robblee, J., McVige, J., Sacco, S., Nahas, S. J., Ailani, J., De Abreu Ferreira, R., Ma, J., Smith, J. H., Dabruzzo, B. & dlt446, dlt446, 2024, In: Journal of Headache and Pain. 25, 1, 10 p., 35.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention

    Pellesi, L., dlt446, dlt446 & Martelletti, P., 2024, In: Expert Opinion on Emerging Drugs. 29, 1, p. 57-64 8 p.

    Research output: Contribution to journal › Review › Research › peer-review

Previous 1 2 Next

ID: 920785